IL40597A - Anti-hypertensively active pharmaceutical preparations containing an anti-hypertensively active amino acid and a beta-hydroxylase inhibitor - Google Patents
Anti-hypertensively active pharmaceutical preparations containing an anti-hypertensively active amino acid and a beta-hydroxylase inhibitorInfo
- Publication number
- IL40597A IL40597A IL40597A IL4059772A IL40597A IL 40597 A IL40597 A IL 40597A IL 40597 A IL40597 A IL 40597A IL 4059772 A IL4059772 A IL 4059772A IL 40597 A IL40597 A IL 40597A
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- amino
- group
- acceptable carrier
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. A pharmaceutical composition containing a) an effective amount of an antihypertensive amino acid compound selected from the group consisting of an a-amino-oc-methyl-fl- (hydroxyla ted phenyl) -propionic acid, a non- oxic salt thereof and an ester thereof; and b) an effective amount of a fi-hydroxyla se inhibitor compound selected from the group consisting of a compound of the formula in which R^ is an esterified, amidised or free carboxyl group and R2 is a lower alkyl group, one of its non-toxic salts, bis- (diethyl thiocarbamoyl) -disulphide and bis-[ (3-aza-3-methyl-hexylene-l ,6)-thiocarbamoyl ] -disulphide ; and c) and a pharmaceutically acceptable carrier.
2. A pharmaceutical composition as claimed in claim 1 containing a) a member selected form the group consisting of a-amino-a-methyl- fl- (4-hydroxyphenyl) -propionic acid , -amino- -methyl- fl- (3 ,4-dihydroxyphenyl) -propionic acid, their non-toxic salts and lower alkyl esters; and b) a member selected from the group consisting of a compoun of the formula wherein ' is lower alkoxycarbonyl , carbamoyl or carboxyl and R2 ' is alkyl with 3-6 C atoms and its salts; and c) a pharmaceutically acceptable carrier.
3. A pharmaceutical composition as claimed in claim 1 containi a) a member selected from the group consisting of a-amino-a-methyl-ft- (4-hydroxyphenyl) -propionic acid, a-amino-a-methyl- P>-(3 ,4-dihydroxyphenyl) -propionic acid, non-toxic salts thereof and lower alkyl esters thereof; and b) a member selected from the group consisting of bis-(diethylthiocarbamoyl) -disulphxde and bis-[ (3-aza-3-methyl-hexylene 1 , 6) -thiocarbamoyl ] -disulphide ; and c) a pharmaceutically acceptable carrier.
4. A pharmaceutical composition as claimed in claim 1 contai ning a) a member selected from the group consisting of a a-amino ά-methyl-R- (4-hydroxyphenyl) -propionic acid , α-amino- -methyl- fl- (3 ,4-dihydroxyphenyl) -propionic acid, alkali metal salts and alkali ne earth metal salts thereof; and b) a member selected from the group consisting of 5-n-pentyl-picolinic acid, 5-n-butyl-picolinic acid, the methyl and ethyl ester and non-toxic salts of one of these compounds; and c) a pharmaceutically acceptable carrier.
5. A pharmaceutical composition as claimed in claim 1 contai ning a) a member selceted from the group consisting of a-amino-a-methyl- ft- (3 ,4-dihydroxyphenyl) -propionic acid, alkali metal salts and alkaline earth metal salts thereof; and b) a member selected from the group consisting of 5-n-butyl-picolinic acid, the methyl and ethyl esters and non-toxic sal thereof; and c) a pharmaceutically acceptable carrier. 401597/2
6. Λ pharmaceutical composition as claimed in claim 1 conta a) a member selected from the group consisting of a-amino-ct-methyl-rt- (3 , -dihydroxyphenyl) -propionic acid and non- toxic salts:. i thereof; and 1 b) a member selected from the group consisting of 5-n-butyl-picolinic acid and its lion-toxic salts; and c) a pharm ceutically acceptable carrier.
7. A pharmaceutical composition as claimed in claim 1 containin a) a member selected from the group consisting of ct-amino- I a-methyl- β- (3 , 4-dihydroxyphenyl) -propionic acid and its non-toxic j salts; and b) bis- (diethylthiocarbamoyl) -disulphide ; and j c) a pharmaceutically acceptable carrier. j
8. A pharmaceutical composition as claimed in claim 1 containin a) a member selected from the group consisting of a-amino- -j methyl- fl- (3 , -dihydroxyphenyl) -propionic acid and its non- oxic salts and b) bis- [ (3-aza-3-methyl-hexylene-l ,6) -thiocarbamoyl ] -disulphide; and c) a pharmaceutically acceptable carrier.
9. A pharmaceutical composition as claimed in claim 1 containing 100-200 mg of -amino-a-methyl- fi- (3 , -dihydroxyphenyl) -propionic acid and 50-200 mg of the calcium salt of 5-n-butyl-picolinic acid and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition as claimed in claim 1 containin 150-200 mg of -amino-a-methyl- fl- (3 , -dihydroxyphenyl) -propionic acid and 100-200 mg of the calcium salt of 5-n-butyl-picolinic acid and a pharmaceutically acceptable carrier.
11. A process for the manufacture of a pharmaceutical compositio dient mentioned under a) and an active ingredient mentioned under b) in any one of claims 1, 2 and 3 are formulated with a pharmaceutically acceptable carrier.
12. A process for the manufacture of a pharmaceutical composition as claimed in any one of claims 4, 5 and 6, wherein an active ingredient mentioned under a) and an active ingredient mentioned under b) in any one of claims 4, 5 and 6 are formulated with a pharmaceutically acceptable carrier.
13. A process for the manufacture of a pharmaceutical composition as claimed in claim 7 or 8 , wherein an active ingredient mentioned under a) and an active ingredient mentioned under b) in claim 7 or 8 are formulated with a pharmaceutically acceptable carrier.
14. A process for the manufacture of a pharmaceutical composition as claimed in claim 9 wherein 100-200 mg of -amino-a-methyl- Λ- (3 ,4-dihydroxyphenyl) -propionic acid and 50-200 mg of the calcium salt of 5-n-butyl-picolinic acid are formulated with a pharmaceutically acceptable carrier.
15. A process for the manufacture of a pharmaceutical composition as claimed in claim 10 wherein 150-200 mg of a-amino-a-methyl- fl- (3 ,4-dihydroxyphenyl) -propionic acid and 100-200 mg of the calcium salt of 5-n-butyl-picolinic acid are formulated with a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1637771 | 1971-11-11 | ||
| CH1354572 | 1972-09-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL40597A0 IL40597A0 (en) | 1972-12-29 |
| IL40597A true IL40597A (en) | 1976-06-30 |
Family
ID=25712489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL40597A IL40597A (en) | 1971-11-11 | 1972-10-17 | Anti-hypertensively active pharmaceutical preparations containing an anti-hypertensively active amino acid and a beta-hydroxylase inhibitor |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US3883656A (en) |
| AU (1) | AU4864272A (en) |
| BE (1) | BE791253A (en) |
| DE (1) | DE2254018A1 (en) |
| FR (1) | FR2159413B1 (en) |
| GB (1) | GB1405949A (en) |
| IE (1) | IE36780B1 (en) |
| IL (1) | IL40597A (en) |
| NL (1) | NL7214607A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389415A (en) * | 1978-01-24 | 1983-06-21 | Merck & Co., Inc. | Method of treating hypertension |
| US4321264A (en) * | 1980-04-14 | 1982-03-23 | Merck & Co., Inc. | α-methyldopa compositions |
| EP0374764B1 (en) * | 1988-12-19 | 2001-04-04 | Nec Corporation | Data transfer apparatus |
-
1972
- 1972-10-17 IL IL40597A patent/IL40597A/en unknown
- 1972-10-17 IE IE1403/72A patent/IE36780B1/en unknown
- 1972-10-27 NL NL7214607A patent/NL7214607A/xx unknown
- 1972-10-30 US US302156A patent/US3883656A/en not_active Expired - Lifetime
- 1972-11-04 DE DE2254018A patent/DE2254018A1/en active Pending
- 1972-11-08 GB GB5151672A patent/GB1405949A/en not_active Expired
- 1972-11-09 AU AU48642/72A patent/AU4864272A/en not_active Expired
- 1972-11-09 FR FR7239713A patent/FR2159413B1/fr not_active Expired
- 1972-11-10 BE BE791253D patent/BE791253A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4864272A (en) | 1974-05-09 |
| AU472689B2 (en) | 1976-06-03 |
| NL7214607A (en) | 1973-05-15 |
| IE36780L (en) | 1973-05-11 |
| IE36780B1 (en) | 1977-02-16 |
| DE2254018A1 (en) | 1973-05-30 |
| BE791253A (en) | 1973-05-10 |
| GB1405949A (en) | 1975-09-10 |
| US3883656A (en) | 1975-05-13 |
| FR2159413B1 (en) | 1975-08-08 |
| FR2159413A1 (en) | 1973-06-22 |
| IL40597A0 (en) | 1972-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES8300112A1 (en) | their starting compounds and their preparation. | |
| GB1222708A (en) | Novel 5-(n-substituted aminomethyl)-2-oxazolidinones and their process of preparation | |
| IE41474L (en) | Thiomethylergolines | |
| GB1437136A (en) | Anti-inflammatory thiazole compounds compositions and methods for using same | |
| IL40597A (en) | Anti-hypertensively active pharmaceutical preparations containing an anti-hypertensively active amino acid and a beta-hydroxylase inhibitor | |
| GB1277239A (en) | Cycloalkane-carboxylic acid derivatives | |
| ES8405006A1 (en) | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof. | |
| RU96101800A (en) | AMIDA DERIVATIVES OF PHENYLCYCLOGAXYLICARBONIC ACID, MIXTURE OF THEIR ISOMERS OR SEPARATE ISOMERES AND THEIR SALT, PHARMACEUTICAL COMPOSITION WITH ANTI-ARTERIOCLEROTIC AND ANTI-RETENCY | |
| GB1348737A (en) | Cephalosporin derivatives | |
| GB1289358A (en) | ||
| GB1173227A (en) | Amino-Isoquinolines | |
| IE34314L (en) | Dibenzodioxocine derivatives | |
| GB1097531A (en) | Improvements in or relating to the preparation of cyclopentane derivatives | |
| US4148879A (en) | Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters | |
| IE45178L (en) | Phenothiazine derivatives | |
| US4148878A (en) | Inhibition of platelet aggregation with selected phosphoric acid esters | |
| GB1291644A (en) | Substituted 1-indancarboxylic acids, their esters and salts | |
| GB1247711A (en) | Antibacterial agents and a process for the preparation thereof | |
| US4086354A (en) | Novel anti-hypertensive compositions | |
| JPH0365338B2 (en) | ||
| GB1385831A (en) | Acylamino-cephem-carboxylic acids and process for their preparation | |
| US2909466A (en) | Stable solutions of oxytetracycline salts | |
| IE41564L (en) | Ergot peptide alkaloids | |
| US3898266A (en) | Methylsulfonyl-benzoic acid derivatives | |
| US3968145A (en) | Methyl 2(1 chloronaphth-2-yloxy)propionate |